Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
The deal covers Streck's cell stabilization and molecular products, including the soon-to-be released Zulu RT, a rapid real-time PCR instrument.
Japan's Pharmaceuticals and Medical Devices Agency approved the use of Quidel's Sofia Influenza A+B Fluorescent Immunoassay on the Sofia Fluorescent Immunoassay Analyzer.
The two parties are exploring opportunities to collaborate on research projects, including next-generation genomics and molecular diagnostic test development.
The study looked at 561 women who received biopsies after inconclusive imaging and found the test could have reduced unneeded biopsies by up to 67 percent.
The firm has acquired two point-of-care, CLIA-waived lateral flow assays to detect biomarkers and pathogens related to dry eye and pink eye.
Following the completion of the recapitalization, participating shareholders released Theranos from any potential claims.
Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.
The firm said it anticipates using the net proceeds from the offering for general corporate purposes and to fund its commercialization efforts.
Rising per test revenues and a slowing cash burn suggest a plausible path to profitability, but to get there the company will likely need to boost sales volume.
The firm is seeking funding to commercialize a malondialdehyde-acetaldehyde-adduct biomarker ELISA that it believes can help broaden access to cardiac tests.
The company's revenues rose to $726,000 from $505,000 in the year-ago quarter, as revenue per OVA1 test performed jumped 33 percent while volume remained flat.
A study demonstrated a connection between Epic's CTC-based PD-L1 assessment and patient outcomes, though clinical validation for immunotherapy prediction is still ongoing.
The deal covers ProteaseTag technology developed at Queen's University of Belfast that the company plans to use in its respiratory disease diagnostics.
The firm said that it received a $5.8 million order to supply test components and intermediate product for producing its chromographic DPP HIV 1/2 Assays in Brazil.
The firm's net loss grew year over year and it missed the consensus Wall Street estimates on the top and bottom lines.
The updated guidance comes on the heels of new data suggesting that for some individuals, antibodies to the Zika virus may stay in the body for months after infection.
The developers maintain that the new assay would address an unmet market need for a DMD screening test.
In separate deals, Poplar Healthcare will pay the federal government nearly $900,000, while Piedmont Pathology will pay $601,000.
According to Roche, the module "offers greater testing efficiency, superior reagent management, and industry-leading turnaround time for critical diagnostic tests."